Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL145634 | 0.85 | SLC6A3 (0.66) | SLC6A3SLC6A4SIGMAR1SLC6A2CHRM3 | |
| SCHEMBL145311 | 0.81 | SLC6A4 (0.61) | SLC6A3SLC6A4SIGMAR1SLC6A2ALDH1A1 | |
| SCHEMBL11047938 | 0.79 | SLC6A3 (0.72) | SLC6A3SLC6A4SIGMAR1SLC6A2CHRM3 | |
| SCHEMBL10831116 | 0.77 | SIGMAR1 (0.71) | SLC6A3SIGMAR1 | |
| SCHEMBL142605 | 0.76 | SLC6A3 (0.77) | SLC6A3SLC6A4SIGMAR1SLC6A2CYP2D6 | |
| SCHEMBL11048826 | 0.76 | SLC6A3 (0.68) | SLC6A3SLC6A4SIGMAR1SLC6A2CHRM3 | |
| SCHEMBL140633 | 0.76 | SLC6A3 (0.68) | SLC6A3SLC6A4SIGMAR1SLC6A2CHRM3 | |
| SCHEMBL141031 | 0.75 | SLC6A2 (0.58) | SLC6A3SLC6A4SIGMAR1SLC6A2OPRK1 | |
| SCHEMBL17923794 | 0.72 | GAA (0.52) | P2RX7GAACYP2C19EPHX1NPC1 | |
| SCHEMBL11046164 | 0.72 | SLC6A3 (0.66) | SLC6A3SLC6A4SIGMAR1SLC6A2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9931346-B2 | Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-04-03 | — | — | US | disclosed |
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2016-10-27 | — | — | US | disclosed |
| EP-3082782-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015091508-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-06-25 | — | — | WO | disclosed |
| CN-101355876-B | Composition suitable for ophthalmic administration | COMBINATORX INC | 2012-09-05 | — | — | CN | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | CombinatoRx, (Singapore) Pte. Ltd. | 2010-04-01 | — | — | US | disclosed |
| US-20050153947-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX | 2005-07-14 | — | — | US | disclosed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040229849-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX, INCORPORATED | 2004-11-18 | — | — | US | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | COMBINATORX, INCORPORATED | 2004-11-04 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004030618-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
| US-4478836-A | 1-Aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives and their use as useful drugs in the treatment of disturbances of the central nervous system | PIERRE FABRE S.A. (FR) | 1984-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160310500-A1 | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS) AND SIGMA RECEPTOR LIGANDS COMBINATIONS | SIGMAR1, OPRL1, SLC6A2 | SLC6A3 29/4885SLC6A4 6/4885SIGMAR1 1/4885 |
| US-20050153947-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | SLC6A3 1714/4885SLC6A4 342/4885SIGMAR1 1612/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | SLC6A3 1670/4885SLC6A4 938/4885SIGMAR1 1247/4885 |
| US-20040220153-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | SLC6A3 1714/4885SLC6A4 342/4885SIGMAR1 1612/4885 |
| US-20040229849-A1 | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines | TNF, IL5, IL6 | SLC6A3 1714/4885SLC6A4 342/4885SIGMAR1 1612/4885 |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | IFNG, IL5, HAVCR2 | SLC6A3 4759/4885SLC6A4 4506/4885SIGMAR1 4580/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | SLC6A3 3683/4885SLC6A4 3269/4885SIGMAR1 4030/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | SLC6A3 3683/4885SLC6A4 3269/4885SIGMAR1 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.